WHO invites manufacturers to submit mpox vaccine EOI for emergency use listing

Call for EOI - 8 August 2024

The WHO has issued an invitation for manufacturers of mpox vaccines to submit an Expression of Interest (EOI) for Emergency Use Listing (EUL). The EUL process is a critical step in ensuring that safe and effective vaccines are made available to countries and populations in need.

The WHO's EUL process is a rigorous scientific assessment of the quality, safety, and efficacy of vaccines. The process involves a review of data from clinical trials, as well as manufacturing and quality control information. Once a vaccine has been granted EUL, it can be procured and used by countries and organizations around the world.

How to submit an EOI

Interested manufacturers should submit their EOI by letter to the WHO's Vaccines Department. The letter should include the following information: * Name and contact information of the manufacturer * Name and description of the mpox vaccine * Data from clinical trials, including safety and efficacy data * Manufacturing and quality control information The WHO will review all EOIs and select a limited number of manufacturers to participate in the EUL process.

Conclusion

The WHO's invitation for EOI is a significant step in addressing the ongoing public health challenge posed by mpox. The EUL process will help to ensure that safe and effective vaccines are made available to countries and populations in need, and will contribute to the global effort to control and eventually eliminate mpox.